These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 21180621)
21. Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms. Iwaki H; Tagawa M; Iwasaki K; Kawakami K; Nomoto M J Neurol Sci; 2019 Jul; 402():145-152. PubMed ID: 31151065 [TBL] [Abstract][Full Text] [Related]
22. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease. Grover ND; Limaye RP; Gokhale DV; Patil TR Indian J Pharmacol; 2013; 45(6):547-55. PubMed ID: 24347760 [TBL] [Abstract][Full Text] [Related]
23. Anticholinergics for symptomatic management of Parkinson's disease. Katzenschlager R; Sampaio C; Costa J; Lees A Cochrane Database Syst Rev; 2003; 2002(2):CD003735. PubMed ID: 12804486 [TBL] [Abstract][Full Text] [Related]
25. Zonisamide for the Efficacy of Sleep Abnormality in Parkinson's Disease (ZEAL Study): A Protocol for Randomized Controlled Trials. Kataoka H; Isogawa M; Inoue T; Hasebe M; Takashima R; Kasama S; Nanaura H; Kiriyama T; Kasahara M; Sugie K Front Neurol; 2021; 12():741307. PubMed ID: 34970203 [No Abstract] [Full Text] [Related]
26. Zonisamide in Parkinson's disease: a current update. Goel A; Sugumaran R; Narayan SK Neurol Sci; 2021 Oct; 42(10):4123-4129. PubMed ID: 34448999 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials. Hasegawa K; Kochi K; Maruyama H; Konishi O; Toya S; Odawara T J Alzheimers Dis; 2021; 79(2):627-637. PubMed ID: 33337365 [TBL] [Abstract][Full Text] [Related]
28. Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson's Disease. Nishijima H; Miki Y; Ueno S; Tomiyama M Parkinsons Dis; 2018; 2018():8626783. PubMed ID: 30662707 [TBL] [Abstract][Full Text] [Related]
29. Genome-wide association study identifies zonisamide responsive gene in Parkinson's disease patients. Cha PC; Satake W; Ando-Kanagawa Y; Yamamoto K; Murata M; Toda T J Hum Genet; 2020 Aug; 65(8):693-704. PubMed ID: 32355309 [TBL] [Abstract][Full Text] [Related]
30. Zonisamide: a new antiepileptic drug. Sobieszek G; Borowicz KK; Kimber-Trojnar Z; Małek R; Piskorska B; Czuczwar SJ Pol J Pharmacol; 2003; 55(5):683-9. PubMed ID: 14704463 [TBL] [Abstract][Full Text] [Related]
31. Zonisamide for neuropathic pain in adults. Moore RA; Wiffen PJ; Derry S; Lunn MP Cochrane Database Syst Rev; 2015 Jan; 1(1):CD011241. PubMed ID: 25879104 [TBL] [Abstract][Full Text] [Related]
32. Zonisamide effects on sleep problems and depressive symptoms in Parkinson's disease. Suzuki K; Fujita H; Matsubara T; Haruyama Y; Kadowaki T; Funakoshi K; Watanabe Y; Hirata K Brain Behav; 2021 Mar; 11(3):e02026. PubMed ID: 33399276 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial. Lu Y; Xiao Z; Yu W; Xiao F; Xiao Z; Hu Y; Chen Y; Wang X Clin Drug Investig; 2011; 31(4):221-9. PubMed ID: 21166480 [TBL] [Abstract][Full Text] [Related]
34. [Effects of switching from dopamine agonists to zonisamide on psychiatric and motor symptoms in patients with Parkinson's disease]. Abe T; Maruyama H Rinsho Shinkeigaku; 2021 Jul; 61(7):449-455. PubMed ID: 34148934 [TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials. Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702 [TBL] [Abstract][Full Text] [Related]
37. A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Guerrini R; Rosati A; Segieth J; Pellacani S; Bradshaw K; Giorgi L Epilepsia; 2013 Aug; 54(8):1473-80. PubMed ID: 23837461 [TBL] [Abstract][Full Text] [Related]
38. Zonisamide: Review of Recent Clinical Evidence for Treatment of Epilepsy. Kwan SY; Chuang YC; Huang CW; Chen TC; Jou SB; Dash A CNS Neurosci Ther; 2015 Sep; 21(9):683-91. PubMed ID: 26205514 [TBL] [Abstract][Full Text] [Related]
39. The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data. Tousi B; Leverenz JB Drug Des Devel Ther; 2021; 15():1811-1817. PubMed ID: 33976533 [TBL] [Abstract][Full Text] [Related]
40. Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials. Tsuboi Y; Nakamura M; Maruyama H; Matsumoto Y J Neurol Sci; 2021 Nov; 430():120026. PubMed ID: 34715471 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]